59 Immunotherapy Toxicities in Real-World Use of Nivolumab & Ipilimumab in Pleural Malignant Mesothelioma: Experience from Sussex Cancer Centre

Data from Checkmate 743 (CM743) study has established Nivolumab/ Ipilimumab (N/I) combination immunotherapy as the first line palliative treatment for Malignant Pleural Mesothelioma (MPM). Since July 2022, N/I have been available on the NHS via the Cancer Drug Fund. We retrospectively assessed the toxicity profile in MPM patients who received N/I as first line palliative treatment.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Mesothelioma Source Type: research